Aperiomics is a precision pathogen testing company that is changing EVERYTHING about how infections are identified. Aperiomics’ Xplore-PATHO™ is a combination of deep metagenomic sequencing and proprietary bioinformatic analysis that can identify 37,000+ microorganisms in a single test. This cutting-edge technology is delivered as a service and detects every known bacteria, virus, parasite, and fungus.
Xplore-PATHO™ is a service that tests samples (human, animal, plant) for the presence of every known microorganism (bacteria, DNA virus, parasite, and fungi) in a single test. This platform technology has broad application across diverse markets such as clinical, agriculture, environment, industry, and veterinary. The impact of Aperiomics’ technologies is substantial due to this unique approach to microbe detection. Instead of blindly probing for a proverbial ‘needle in a haystack’, Aperiomics’ approach analyzes the entire ‘haystack’, harnessing the power of deep metagenomic sequencing and bioinformatics to identify every ‘needle’. Xplore-PATHO™ is transformative and is changing pathogen identification forever.
Existing pathogen testing, simply put, is inadequate; up to 80% of infections go undiagnosed. Undiagnosed infection costs the US economy billions each year (undiagnosed fungi alone cost $26B). Further, existing tests require one to know what they are looking for; Aperiomics’ approach identifies every known microorganism, even if you don’t know what you are looking to find. Deep sequencing is the future of pathogen testing and has already disrupted cancer testing markets. Data analysis for sequencing is often more expensive than the generation of raw sequencing data and is a major bottleneck to adoption in pathogen testing. For sequencing to reach its full potential of revolutionizing pathogen identification, data analysis must be robust, simplified, and automated. Aperiomics’ Xplore-PATHO™ does just this, providing a cost-effective method to detect 37,000+ microorganisms in ONE test.